Caroline Godfrey, PepGen CEO
December 9, 2020 10:34 AM ESTUpdated 10:56 AM
Financing

RA Cap­i­tal backs Ox­ford spin­out Pep­Gen with a $45M Se­ries A, seek­ing to treat Duchenne and oth­er sim­i­lar dis­eases

Max Gelman

Senior Editor

Less than two months af­ter Pe­ter Kolchin­sky and Raj Shah an­nounced a new $461 mil­lion fund, the part­ners at RA Cap­i­tal Man­age­ment ap­pear to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Biotech VC firm out­lines plans for $100M fund

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Gilead­'s Kite un­cou­ples from Fo­s­un in Chi­na as Yescar­ta faces cov­er­age ob­sta­cles

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times